6:32 PM
 | 
Jul 30, 2014
 |  BC Extra  |  Top Story

AZ to acquire Almirall's respiratory business

AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire the respiratory disease business of Almirall S.A. (Madrid:ALM) for $875 million up front and up to $1.2 billion in milestones. The business had 1H14 sales of EUR 123.5 million ($168.6 million). The deal is expected to close by year end.

AZ will gain Almirall's...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >